Search Results

Paulzen, M.: Psychotropic Medication and Breastfeeding – Yes – No – Maybe? Pharmacopsychiatry; Issue 02, 2024

Petri, H.: The influence of food on the pharmacokinetics of drugs Pharmacopsychiatry; Issue 02, 2024

Weiner, R.M.: PGx and/or TDM? How could they interact in daily practice? Pharmacopsychiatry; Issue 02, 2024

Zernig, G.: Degree of clinically quantified tolerance to the desired effects of and adverse drug reactions to the full mu opiod receptor agonist morphine, methadone and fentanyl and to the partial agonist buprenorphine during opioid maintenance and analgesic treatment Pharmacopsychiatry; Issue 02, 2024

Smigielski, L.; Tini, E.; Walitza, S.; Frey, M.; Egberts, K.: Therapeutic drug monitoring of children and adolescents treated with escitalopram in daily clinical practice Pharmacopsychiatry; Issue 02, 2024

Spangemacher, M.; Schmitz, C.; Färber, L. V.; Hart, X. M.; Gründer, G.: PET-derived modelling of D2-receptor occupancy of antipsychotic polypharmacy in patients with schizophrenia Pharmacopsychiatry; Issue 02, 2024

Menke, A.: Pharmacogenetic testing for selection of antidepressant treatment Pharmacopsychiatry; Issue 02, 2024

Kittel-Schneider, S.: Update on the Management of Lithium in the Peripartum Period Pharmacopsychiatry; Issue 02, 2024

Jung, A.; Fekete, S.; Taurines, R.; Egberts, K.: Haloperidole serum concentrations in daily child and adolescent psychiatric practice Pharmacopsychiatry; Issue 02, 2024

Schwarz, M.: International Guidelines of pharmacogenetic testing focusing on pharmacokinetically relevant genes and there relevance in neuropsychopharmacology Pharmacopsychiatry; Issue 02, 2024

von Broen, M.; Scherf-Clavel, M.; Deckert, J.; Unterecker, S.: Sertraline concentration in serum unaffected by hemodialysis: a case report Pharmacopsychiatry; Issue 02, 2024

Toto, S.; Grohmann, R.; Bleich, S.; Seifert, J.: Drug safety in special populations: current data from the AMSP Project Pharmacopsychiatry; Issue 02, 2024

Molden, E.: Identifying CYP2C19 and CYP2D6 poor metabolizers from TDM data Pharmacopsychiatry; Issue 02, 2024

Liang, J.; de Winter, B.C. M.; Hermans, R. A.; Kloosterboer, S. M.; Bayraktar, I.; Hillegers, M.H. J.; van den Berg, S.A. A.; Koch, B.C. P.; Dierckx, B.: Risperidone plasma concentrations and side effects/effectiveness in children and adolescents with autism spectrum disorder Pharmacopsychiatry; Issue 02, 2024

Zioris, G.; Warrings, B.; Heiduk, S.; Deckert, J.; Unterecker, S.; Scherf-Clavel, M.: Drug-drug interaction between hydroxybupropion and venlafaxine – a pharmacokinetic study on CYP2D6 Pharmacopsychiatry; Issue 02, 2024

Hart, X. M.: Therapeutic Drug Monitoring of Antipsychotics: Innovations in the 2024 Consensus Guidelines Pharmacopsychiatry; Issue 02, 2024

Scherf-Clavel, M.; Frantz, A.; Eckert, A.; Weber, H.; Unterecker, S.; Deckert, J.; Reif, A.; Hahn, M.: Equal contribution of pharmacogenetic phenotype and phenoconversion to functional CYP2D6 metabolizer status Pharmacopsychiatry; Issue 02, 2024

Kuzin, M.: Therapeutic drug monitoring in the opioid substitution treatment Pharmacopsychiatry; Issue 02, 2024

Brauner, M.L.; Geffert, C.; Lukačin, R.; Clement, H.W.; Fleischhaker, C.: Clozapine Monitoring in Serum and Saliva Pharmacopsychiatry; Issue 02, 2024

Taurines, R.; Kunkel, G.; Fekete, S.; Gerlach, M.; Romanos, M.; Egberts, K.: Fluvoxamine serum concentrations in children and adolescents – preliminary results of a multicenter Therapeutic Drug Monitoring (TDM) trial Pharmacopsychiatry; Issue 02, 2024